Elderly (>=75) small-cell lung cancer (SCLC) chemotherapy: A phase I study of carboplatin (CBDCA) and etoposide (vp-16).

@article{Fukuda2004ElderlyS,
  title={Elderly (>=75) small-cell lung cancer (SCLC) chemotherapy: A phase I study of carboplatin (CBDCA) and etoposide (vp-16).},
  author={Minoru Fukuda and Masato Oka and Yoshifumi Soejima and Akira Kinoshita and Hiroshi Takatani and Takashi Kasai and Masaaki Kuba and Hisashi Soda and Shigeru Kohno},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2004},
  volume={22 14_suppl},
  pages={7217}
}
7217 Background: Elderly patients (>=75 year-old) have a great risk for chemotherapy, however, appropriate chemotherapy has improved survival and QOL in patients (pts) with SCLC. The combination with cisplatin and VP-16 is an active regimen for SCLC, and CBDCA is an analogue of cisplatin with less nonhematological toxicity. Based on these findings, we… CONTINUE READING